PLURISTEM THERAPEUTICS

PLURISTEM THERAPEUTICS

Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD cells, which is Phase III clinical trial ... for the treatment of critical limb ischemia (CLI) in patients unsuitable for revascularization, recovery after surgery for hip fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of ARS. The company has a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermittent claudication; and nTRACK, a collaborative project with Leitat to examine gold nano particles labeling of stem cells. It also has collaboration agreements with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions; and BIH Center for Regenerative Therapy and Berlin Center for Advanced Therapies to expand its framework and research agreement, as well as conduct a joint project evaluating the therapeutic effects of the registrant's patented PLX cell product candidates for treatment of the respiratory and inflammatory complications associated with the COVID-19 coronavirus. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.

Pluristem Therapeutics_logo

Industry:
Israeli Company

Founded:
5/11/2001

Address:
Building No. 5, Haifa, Israel Zipcode 31905

Country:
Israel

Phone:
972 7 4710 8600

Market Cap:
485.01M
Total Revenue:
23k
Total Assets:
65.53M
Total Cash:
8.27M

Parent organization: Yeda Research & Development Co Ltd


Key Executives
Name Title Pay Year Born
Mr. Zami Aberman Exec. Chairman 501,244$ 1954(66 years old)
Mr. Yaky Yanay Pres, CEO & Director 350,291$ 1971(49 years old)
Ms. Chen Franco-Yehuda CFO, Treasurer & Sec. 207,690$ 1983(37 years old)
Mr. Lior Raviv VP of Operations & Devel. N/A N/A
Ms. Dana Rubin Director of Investor Relations N/A N/A
Ms. Efrat Kaduri Director of Bus. Devel. & Marketing N/A N/A
Ms. Efrat Livne-Hadass VP of HR N/A N/A
Dr. Nitsan Halevy Chief Medical Officer N/A N/A



Financial & Stock
Company's stock symbol is PSTI.TA. Lastest price : 1,517.00. Total volume :14.07k Click reload if you want to check the lastest price on market!!!


Site Inspections: http://www.pluristem.com

  • Host name: just57.justhost.com
  • IP address: 173.254.28.57
  • Location: Provo United States
  • Latitude: 40.2342
  • Longitude: -111.6442
  • Metro Code: 770
  • Timezone: America/Denver
  • Postal: 84606

Loading ...
Loading ...


More informations about "Pluristem Therapeutics" on Search Engine

Pluristem Therapeutics, Inc. (PSTI) Stock Price, News

Finance.yahoo.com About PluristemPluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates.

Coronavirus disease -COVID-19 - Pluristem Therapeutics Inc

Pluristem.com Pluristem’s cell therapy is designed to treat various medical conditions and is being evaluated in several advanced clinical studies, as can be found in this website under ‘Clinical Programs’. PLX cells* may reduce the severity of COVID-19 pneumonia, hopefully leading to a better prognosis for the patients.

Pluristem Therapeutics - Wikipedia

En.wikipedia.org Pluristem Therapeutics is an Israeli company engaged in the development of human placental adherent stromal cells for commercial use in disease treatment. According to the company's website, it extracts adult stem cells exclusively from postnatal placentas.

PSTI Stock Price | Pluristem Therapeutics Inc. Stock Quote

Marketwatch.com Pluristem Therapeutics, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple...

Boiling and ready to burst as Pluristem Therapeutics Inc

Investchronicle.com Mar 19, 2021 · Pluristem Therapeutics Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $9.89 on 01/11/21, with the lowest value was $4.30 for the same time period, recorded on 03/05/21. Pluristem Therapeutics Inc. (PSTI) full year performance was 75.00%

Pluristem Therapeutics, Inc. (PSTI) Stock Forum

Finance.yahoo.com Pluristem Therapeutics Inc (NASDAQ: PSTI): Sold 121,919 shares of the Israeli-based stemcell company, representing about 0.0063% of the ETF. Pluristem shares closed 0.84% higher at $4.81 on ...

Here's Why Pluristem Therapeutics Jumped Over 28% Today

Fool.com Apr 25, 2020 · To be blunt, Pluristem Therapeutics is a stem cell stock that doesn't belong in your portfolio. The company sported a market valuation of only …

Should I buy Pluristem Therapeutics, Inc. (PSTI) - Zacks

Zacks.com Apr 09, 2021 · In addition, Pluristem Therapeutics, Inc. has a VGM Score of F (this is a weighted average of the individual Style Scores which allow you to focus on the stocks that best fit …

Pluristem Therapeutics: The Search For An ARDS Treatment

Seekingalpha.com May 19, 2020 · Pluristem Therapeutics (PSTI) is one of the companies which received significant financing to work on COVID-19 and ARDS-related treatments. Pluristem Therapeutics is an Israeli company. It signed a...

Pluristem Therapeutics Inc. (PSTI : NASDAQ) Stock Price

Google.com Pluristem Therapeutics is an Israeli company engaged in the development of human placental adherent stromal cells for commercial use in disease treatment. According to the company's website, it ...

Pluristem Therapeutics, Inc. - PSTI - Stock Price Today

Zacks.com Apr 09, 2021 · PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative ...

PSTI Stock Forecast, Price & News (Pluristem Therapeutics)

Marketbeat.com Mar 31, 2021 · Pluristem Therapeutics' stock was trading at $2.89 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PSTI shares have increased by 66.4% and is now trading at $4.81. View which stocks have been most impacted by COVID-19.

Pluristem Therapeutics Treats First COVID-19 Patient In U

Nasdaq.com Apr 13, 2020 · Pluristem Therapeutics is a regenerative medicine company developing placenta-based cell therapy product candidates. The views and opinions expressed herein …

Pluristem Therapeutics Sees Unusually Large Options Volume

Marketbeat.com Pluristem Therapeutics Inc. (NASDAQ:PSTI) was the recipient of some unusual options trading on Tuesday. Investors purchased 9,151 call options on the stock. This represents an increase of 530% compared to the typical volume of 1,452 call options.

Pluristem Therapeutics Inc. Announces $30 Million

Marketwatch.com Feb 02, 2021 · Pluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported robust clinical trial data in...

Combined Holdings of Pluristem Therapeutics Inc. (PSTI)

Cathiesark.com Combined Holdings of Pluristem Therapeutics Inc. (PSTI) - Updated Daily. Shares Held Weight In Portfolio. Trades of PSTI Made In All Funds. Why do the number of shares of a company held in an Ark ETF go up or down even when no trades are reported? Date. Direction. Shares. Fund Weight.

Pluristem Therapeutics (PSTI) Stock Price, News & Info

Fool.com Pluristem Therapeutic is a bio-therapeutics Company dedicated to the commercialization of non-personalized cell therapy products for the treatment of several severe degenerative ischemic and...

Pluristem Therapeutics: Behind The Massive Rally (NASDAQ)

Seekingalpha.com Pluristem Therpaeutics (PSTI) is a Haifa, Israel-based clinical stage regenerative medicine company that. In 2003, the NASDAQ-listed shell company A1 Software acquired all shares and patents...

Pluristem Therapeutics Inc. Announces $30 Million

Markets.businessinsider.com Feb 02, 2021 · Pluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported robust clinical trial data in...

Pluristem Therapeutics Company Profile - Office Locations

Craft.co Mar 29, 2021 · Pluristem Therapeutics is a clinical-stage biotherapy company developing cell therapies. It uses placental cells and a three-dimensional (3D) technology platform to treat conditions such as inflammation, ischemia, muscle injuries, hematological disorders, and exposure to radiation.

Pluristem (@pluristem) • Twitter

Twitter.com The latest tweets from @Pluristem

Pluristem Therapeutics - Crunchbase Company Profile & Funding

Crunchbase.com Pluristem Therapeutics is a clinical-stage biotechnology company using placental cells and a unique, proprietary, three-dimensional (3D) technology platform to develop cell therapies for a broad spectrum of diseases. Pluristem derives its cell products from human placental cells. These cells are converted into PLacental eXpanded (PLX) cells, which

Pluristem Therapeutics, Inc. (PSTI) Stock Price, News

Ca.finance.yahoo.com Pluristem Therapeutics Inc. Announces $30 Million Registered Direct Offering. HAIFA, Israel, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products (“Pluristem” or the “Company”), today announced it has entered into definitive agreements with ...

Israeli firm hopeful as it starts treating COVID-19

Timesofisrael.com Jun 06, 2020 · Pluristem Therapeutics uses placentas to grow smart cells, and programs them to secrete therapeutic proteins in the bodies of sick people. It …

Looking Closely at the Growth Curve for Pluristem

Newsheater.com Dec 09, 2020 · Pluristem Therapeutics Inc. (NASDAQ:PSTI) went down by -36.47% from its latest closing price compared to the recent 1-year high of $13.29. The company’s stock price has collected 14.83% of gains in the last five trading sessions. The Wall Street Journal reported 1 hour ago that DoorDash, GameStop, Pfizer: What to Watch When the Stock Market Opens Today

PSTI:Tel Aviv Stock Quote - Pluristem Therapeutics Inc

Bloomberg.com Pluristem Therapeutics, Inc. develops Messenchymal stem cell production technology and commercializes cell therapy products. The Company focuses on cell therapy to treat severe blood ...

PSTI | Pluristem Therapeutics Inc. Stock Price & News - WSJ

Wsj.com Pluristem Therapeutics, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple...

PSTI: Pluristem Therapeutics Inc - Stock Price, Quote and

Cnbc.com Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions.

Pluristem Therapeutics, Interview with Yaky Yanay

Bioinformant.com Mar 28, 2019 · Pluristem Therapeutics (PSTI) is a clinical-stage company that is a proprietary 3D manufacturing technology to develop placental cell therapies for conditions that include ischemia, muscle injury, and exposure to radiation. I had the honor of interviewing Mr. Yaky Yanay, President and Co-CEO of Pluristem Therapeutics.. In this interview, we discuss the history of Pluristem Therapeutics, its ...

Pluristem Therapeutics Company Profile: Stock Performance

Pitchbook.com Pluristem Therapeutics General Information Description. Pluristem Therapeutics Inc is a US-based company that acts as a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory, and hematologic conditions.

Pluristem Therapeutics (PSTI) Stock Price, Quote & News

Stockanalysis.com Apr 07, 2021 · About PSTI. Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.

Pluristem Therapeutics Stock Quote. PSTI - Stock Price

Ih.advfn.com Pluristem Therapeutics Inc is a US-based company that acts as a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory, and hematologic conditions. The lead indications are critical limb ischemia, recovery after surgery for femoral neck fracture, and acute radiation syndrome.

Pluristem Therapeutics | LinkedIn

Linkedin.com Pluristem Therapeutics | 8,486 followers on LinkedIn. Pluristem Therapeutics Inc. (NasdaqCM: PSTI, TASE: PSTI/PLTR) is a clinical-stage biotherapy company using placental cells and a unique ...

Pluristem Therapeutics Inc. (PSTI) has risen 6.04% Friday

Investorsobserver.com Mar 19, 2021 · Pluristem Therapeutics Inc. currently has the 138th highest Short-Term Technical score in the Biotechnology industry. The Short-Term Technical score evaluates a stock's trading pattern over the past month and is most useful to short-term stock and option traders. Pluristem Therapeutics Inc.'s Overall and Short-Term Technical score paint a mixed ...

PSTI Stock Price, Pluristem Therapeutics Stock Quotes and

Benzinga.com Jan 01, 2019 · Pluristem Therapeutics Inc is a US-based company that acts as a developer of placenta-based cell therapy product candidates for the treatment of …

Buy shares of Pluristem Therapeutics Inc. stock (PSTI) | Stash

Stash.com Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. Thanks to fractional shares

Pluristem Therapeutics - Stock Price History | PSTI

Macrotrends.net Historical daily share price chart and data for Pluristem Therapeutics since 2021 adjusted for splits. The latest closing stock price for Pluristem Therapeutics as of March 29, 2021 is 4.48.. The all-time high Pluristem Therapeutics stock closing price was 3700.00 on July 15, 2003.; The Pluristem Therapeutics 52-week high stock price is 13.29, which is 196.7% above the current share price.

Pluristem Therapeutics (NasdaqGM:PSTI) - Share price, News

Simplywall.st Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, …

Pluristem Therapeutics Inc. Announces $30 Million

Stockhouse.com Feb 02, 2021 · Pluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell product candidates and is currently conducting late-stage clinical trials in several indications.

We're Keeping An Eye On Pluristem Therapeutics' (NASDAQ)

News.yahoo.com Mar 05, 2021 · Does Pluristem Therapeutics Have A Long Cash Runway? A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. When Pluristem Therapeutics last reported its balance sheet in …

Pluristem Therapeutics Inc (PSTI) Quote - XNAS | Morningstar

Morningstar.com Apr 09, 2021 · Pluristem Therapeutics Inc is a US-based company that acts as a developer of placenta-based cell therapy product candidates for the treatment of …

Pluristem News and latest stories | The Jerusalem Post

Jpost.com The survival rate is 87.5%, Pluristem Therapeutics reported. By MAAYAN JAFFE-HOFFMAN. 16/05/2020. Israel's Pluristem FDA approved for study in treatment of severe COVID-19.

Pluristem names members of coronavirus Steering Committee

Jpost.com Oct 25, 2020 · Pluristem names members of coronavirus Steering Committee The committee is composed of five prominent infectious diseases, critical care, internal medicine and pumonology specialists from around ...

PSTI Stock | Message Board | Pluristem Therapeutics

Investorshangout.com Dec 29, 2020 · PSTI Stock Message Board for Investors. Pluristem Therapeutics Stock Price, News and Company Updates. Message Board Total Posts: 68

PSTI.O - Pluristem Therapeutics Inc. News | Reuters

Reuters.com Pluristem Therapeutics Inc, a developer of placenta-based stem cell products, said the U.S. Food and Drug Administration has cleared the emergency use of its therapy to treat acute radiation ...

PSTI:NASDAQ GM Stock Quote - Pluristem Therapeutics Inc

Bloomberg.com Pluristem Therapeutics, Inc. develops Messenchymal stem cell production technology and commercializes cell therapy products. The Company focuses on cell therapy to treat severe blood ...